LINC02613: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02613

NCBI ID: G101929596

LINC02613

Other Name(s): long intergenic non-protein coding RNA 2613 | Long intergenic non-protein coding RNA 2613

LINC02613: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02613 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as a potential drug target or biomarker. It is a non-coding RNA molecule that is expressed in various tissues and cell types in the human body. The function of LINC02613 is not well understood, but its potential involvement in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders has led to a growing interest in its study.

Drug Target Potential

LINC02613 has been identified as a potential drug target due to its unique structure and its expressed levels in various tissues. It is a small RNA molecule that has a length of approximately 220 nucleotides and is expressed in various tissues, including the brain, heart, liver, and muscle. The expression level of LINC02613 has been shown to be regulated by various factors, including gene expression, DNA methylation, and post-transcriptional modification.

One of the key features of LINC02613 is its nuclear export, which suggests that it may be involved in the regulation of gene expression. The nuclear export of LINC02613 has been shown to be regulated by various factors, including the heat shock protein (HSP) complex and the RNA-protein interaction.

In addition, LINC02613 has been shown to interact with various protein molecules, including the protein encoded by the gene IPF1. IPF1 is a heat shock protein that is expressed in various tissues and is involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. The interaction between LINC02613 and IPF1 suggests that LINC02613 may be involved in the regulation of IPF1-mediated cellular processes.

Biomarker Potential

The potential use of LINC02613 as a biomarker has also been identified due to its unique expression patterns. LINC02613 has been shown to be expressed in various tissues and cell types, including the brain, heart, liver, and muscle. The expression level of LINC02613 has been shown to be regulated by various factors, including gene expression, DNA methylation, and post-transcriptional modification.

One of the potential applications of LINC02613 as a biomarker is its potential to serve as a diagnostic biomarker for various diseases, including cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells, leading to the formation of tumors. LINC02613 has been shown to be involved in the regulation of various cellular processes that are involved in cancer development, including cell growth, apoptosis, and angiogenesis.

In addition, LINC02613 has also been shown to be involved in the regulation of immune responses, which are critical for cancer immune surveillance. The immune response is a critical mechanism that helps to eliminate cancer cells from the body. LINC02613 has been shown to be involved in the regulation of immune cell function, including the regulation of T cell development and function.

Conclusion

In conclusion, LINC02613 is a long intergenic non-protein-coding RNA that has been identified as a potential drug target or biomarker. Its unique structure and its expressed levels in various tissues make it an attractive candidate for further study. Further research is needed to fully understand the function of LINC02613 and its potential involvement in diseases such as cancer and autoimmune disorders.

Protein Name: Long Intergenic Non-protein Coding RNA 2613

The "LINC02613 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02613 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets